Dietary Supplements

On June 11, 2007, FDA requested that industry organizations submit notification expressing their desire to participate in the selection process for nonvoting industry representatives on the Food Safety Public Advisory Committee. Please accept this letter as an official request from CHPA to assist in the selection process.

CHPA Dietary Supplements Committee members fully support the proposed changes to the labeling requirements for health claims regarding calcium and osteoporosis. These proposed changes amend the regulation authorizing health claims on the relationship between calcium and a reduced risk of osteoporosis.

The Consumer Healthcare Products Association welcomes the opportunity to present its recommendations for CFSAN’s top priorities for the upcoming fiscal year and congratulates FDA on its achievements of the previous year.

CHPA appreciates the opportunity to provide comments to the Food and Drug Administration on the proposed experimental study of qualified health claims about omega-3 fatty acids.

The CHPA Dietary Supplements Committee supports maintaining A-priority level for several goals listed in the 2005 Program Priorities that specifically address dietary supplement issues. We also support efforts to fully implement the Dietary Supplement Health and Education Act of 1994 as currently written.

Members of the Consumer Healthcare Products Association appreciate the opportunity to nominate an industry representative to serve on the FDA Food Advisory Committee.

CHPA appreciates the opportunity to provide comments concerning U.S. Government positions in preparation for the 33rd session of the Codex Committee on Food Labelling of the Codex Alimentarius Commission.

CHPA appreciates the opportunity to provide comments on the premarket notification for new dietary ingredient (NDI) notifications for dietary supplements.